Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Sarclisa (isatuximab-irfc)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

ImmunoGen, Sanofi

Drug class:

CD38 inhibitor

Related drugs:

‹

daratumumab (26)

daratumumab/hyaluronidase (4)

daratumumab (26)

daratumumab/hyaluronidase (4)

›

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	isatuximab-irfc Sensitive: A1 - Approval isatuximab-irfc Sensitive : A1	isatuximab-irfc Sensitive: A1 - Approval isatuximab-irfc Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide + isatuximab-irfc Sensitive: A1 - Approval pomalidomide + isatuximab-irfc Sensitive : A1	pomalidomide + isatuximab-irfc Sensitive: A1 - Approval pomalidomide + isatuximab-irfc Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	isatuximab-irfc Sensitive: A1 - Approval isatuximab-irfc Sensitive : A1	isatuximab-irfc Sensitive: A1 - Approval isatuximab-irfc Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	carfilzomib + isatuximab-irfc Sensitive: A2 - Guideline carfilzomib + isatuximab-irfc Sensitive : A2	carfilzomib + isatuximab-irfc Sensitive: A2 - Guideline carfilzomib + isatuximab-irfc Sensitive : A2
Chr amplification(1)(q21)	Multiple Myeloma	Chr amplification(1)(q21)	Multiple Myeloma	pomalidomide + isatuximab-irfc Sensitive: B - Late Trials pomalidomide + isatuximab-irfc Sensitive : B	pomalidomide + isatuximab-irfc Sensitive: B - Late Trials pomalidomide + isatuximab-irfc Sensitive : B
Chr amplification(1)(q21)	Multiple Myeloma	Chr amplification(1)(q21)	Multiple Myeloma	lenalidomide + isatuximab-irfc Sensitive: B - Late Trials lenalidomide + isatuximab-irfc Sensitive : B	lenalidomide + isatuximab-irfc Sensitive: B - Late Trials lenalidomide + isatuximab-irfc Sensitive : B
Chr t(14;16)	Multiple Myeloma	Chr t(14;16)	Multiple Myeloma	lenalidomide + isatuximab-irfc Sensitive: B - Late Trials lenalidomide + isatuximab-irfc Sensitive : B	lenalidomide + isatuximab-irfc Sensitive: B - Late Trials lenalidomide + isatuximab-irfc Sensitive : B
Chr t(4;14)	Multiple Myeloma	Chr t(4;14)	Multiple Myeloma	lenalidomide + isatuximab-irfc Sensitive: B - Late Trials lenalidomide + isatuximab-irfc Sensitive : B	lenalidomide + isatuximab-irfc Sensitive: B - Late Trials lenalidomide + isatuximab-irfc Sensitive : B
Chr del(17p)	Multiple Myeloma	Chr del(17p)	Multiple Myeloma	lenalidomide + isatuximab-irfc Sensitive: B - Late Trials lenalidomide + isatuximab-irfc Sensitive : B	lenalidomide + isatuximab-irfc Sensitive: B - Late Trials lenalidomide + isatuximab-irfc Sensitive : B
CD38 positive	Multiple Myeloma	CD38 positive	Multiple Myeloma	isatuximab-irfc + K-NK004 Sensitive: D – Preclinical isatuximab-irfc + K-NK004 Sensitive : D	isatuximab-irfc + K-NK004 Sensitive: D – Preclinical isatuximab-irfc + K-NK004 Sensitive : D
CD38 expression	B Acute Lymphoblastic Leukemia	CD38 expression	B Acute Lymphoblastic Leukemia	isatuximab-irfc Sensitive: D – Preclinical isatuximab-irfc Sensitive : D	isatuximab-irfc Sensitive: D – Preclinical isatuximab-irfc Sensitive : D
CD38 expression	T Acute Lymphoblastic Leukemia	CD38 expression	T Acute Lymphoblastic Leukemia	isatuximab-irfc Sensitive: D – Preclinical isatuximab-irfc Sensitive : D	isatuximab-irfc Sensitive: D – Preclinical isatuximab-irfc Sensitive : D